Abstract Topics

​​​The abstract topics for AD/PDTM 2017 are currently being developed.

The AD/PDTM 2015 abstract submission was classified according to Themes (A-I), Topics (1-10) and Sub-Topics (a-z) as described below:


Th​emes (A-I)
Aβ-Amyloid Diseases
Alzheimer's disease (AD), Prodromal AD, Cerebral amyloid angiopathy (CAA), Down syndrome (DS) & Minimal cognitive impairment (MCI)
Bα-Synucleinopathies
Parkinson's disease (PD), PD Dementia, Dementia with Lewy bodies (DLB), Multiple system atrophy (MSA), Olivopontocerebellar atrophy (OPCA) & AD
CTDP-43 Proteinopathies
Amyotrophic lateral sclerosis (ALS), Frontotemporal lobar degeneration (FTLD), Frontotemporal dementia (FTD), ALS-FTD Spectrum Diseases & AD
DTauopathies
AD, Progressive supranuclear palsy (PSP), Corticobasal degeneration (CBD), Pick's Disease & Chronic traumatic encephalopathy
EPrion Diseases
Creutzfeldt-Jakob disease (CJD), Fatal familial insomnia (FFI) & Gerstmann-Straussler-Scheinker disease (GSSS)
FOther Proteinopathies
Huntington's disease (HD) & Other Protein Misfolding Diseases
GVascular Dementia, Multi-infarct dementia (MID), White Matter Disease & Stroke​
​​
HDemyelinating Diseases
Multiple sclerosis (MS), Leucodystrophy
IOther Neurodegenerative, Motor, Affective & Behavioral Disorders


Topics 1-10Subtopics a-z
1Protein Misfolding &
Aggreg​ation
1.a tau
1.b Abeta
1.c alpha-synuclein
1.d TDP-43
1.e SOD-1
1.f FUS
1.g parkin
1.h PrP
1.i huntingtin
1.j dipeptide repeat proteins
1.k clearance of misfolded proteins
1.l computer simulations
1.m other
2Cell, Molecular &
Systems Biology
2.a APP, APLP, Abeta
2.b tau
2.c alpha-synuclein
2.d TDP-43
2.e FUS
2.f parkin
2.g SOD-1
2.h PINK1
2.i DJ-1
2.j LRKK2
2.k PrP
2.l huntingtin
2.m ApoE
2.n secretases
2.o IAPP
2.p TTR
2.q protein degradation, proteasome & autophagy
2.r growth factors
2.s GCPR, nicotinic, sigma-1 & other receptors
2.t protein-protein interactions & connectome
2.u network biology
2.v metabolomics
2.w transcriptomics
2.x synaptic plastcity
2.y modeling of disease progression
2.z other
3Pathophysiology &
Disease Mechanisms
3.a cell to cell transmission and spreading of pathology
3.b prion-like mechanisms
3.c synapse pathology
3.d autophagy and lysosomes
3.e proteasome and ubiquitin
3.f oxidative damage
3.g mitochondrial dysfunction
3.h metabolism and insulin
3.i inflammation
3.j autoimmunity
3.k lipids, lipoproteins and membrane trafficking
3.l translational regulation
3.m micro RNAs
3.n kinases and phosphatases
3.o cellular signalling
3.p cell-cycle
3.q blood-brain barrier & transport
3.r vasculature & neoangiogenesis
3.s neurogenesis and stem cells
3.t glial cells
3.u cell death
3.v metal ions
3.w calcium homeostasis
3.x neural networks & plasticity
3.y aging
3.z other
4Therapeutic Targets &
Mechanisms for Treatment
4.a immunotherapy
4.b Abeta, truncated & pGlu-Abeta
4.c tau
4.d alpha-synuclein
4.e TDP-43
4.f SOD-1
4.g kinases
4.h secretases & other proteases
4.i other enzymes
4.j neurotransmitter-based targets
4.k nicotinic & other ionotropic receptors
4.l sigma-1, metabotropic, muscarinic and other GPCRs
4.m wnt signalling
4.n anti-inflammatory targets
4.o anti-oxidants
4.p neurotrophic factors
4.q cell transplantation
4.r protein aggregation
4.s misfolding and chaperones
4.t gene therapy
4.u RNAi-based therapy
4.v synaptic plasticity and repair
4.w adult neurogenesis
4.x deep brain stimulation
4.y neurosurgery
4.z other
5Drug Development &
Clinical Trials
5.a active vaccination
5.b antibody-based immunotherapy
5.c beta-secretase inhibitors
5.d gamma-secretase modulators
5.e tau modifyers
5.f amyloid clearance
5.g immunomodulators
5.h hormones
5.i vitamins, anti-oxidants & neuroprotective compounds
5.j neurotransmitter modulators
5.k GPCR ligands
5.l nicotinic & ionotropic ligands
5.m antiepileptics
5.n mitochondrial drugs
5.o RNA-based therapy
5.p cell-based therapies
5.q deep brain stimulation
5.r transcranial magnetic stimulation
5.s nanotechnology
5.t medicinal chemistry approaches
5.u QSAR, X-ray christallography
5.v structure-activity relationships
5.w drug-delivery systems
5.x non-pharmacological interventions
5.y other
6Imaging & Biomarkers
6.a structural MRI
6.b functional MRI
6.c PET - amyloid
6.d PET - alpha-synuclein
6.e PET - tau
6.f PET - glucose
6.g PET - receptors
6.h PET - oxygen
6.i PET - enzymes
6.j PET - other
6.k CT
6.l PET-CT
6.m SPECT imaging
6.n multimodal imaging
6.o EEG & brain mapping
6.p near infrared spectroscopy
6.q MR spectroscopy
6.r other
7Epidemiology, Risk Factors,
Genetics & Epigenetics
7.a aging
7.b environmental
7.c metabolic
7.d cardiovascular
7.e infectious
7.f inflammation
7.g autoimmune
7.h drug-induced
7.i genetic associations & susceptibility genes
7.j GWAS
7.k disease-causing mutations
7.l whole genome sequencing
7.m micro RNA
7.n non-coding RNA
7.o histone modification, DNA methylation
7.p other epigenetic factors
7.q other
8Animal Models
8.a transgenic mice
8.b transgenic rats
8.c primate models
8.d drosophila
8.e zebra fish
8.f pharmacological & lesion models
8.g natural & seminatural models
8.h other
9Patient Care & Support
9.a caregiver support
9.b mobile applications
9.c web-based care
9.d physician networks
9.e social networks
9.f cognitive training
9.g art, music & life style
9.h functional foods
9.i other
10Other
10.a cell, molecular & systems biology
10.b disease mechanisms
10.c preclinical research
10.d diagnostics
10.e imaging
10.f clinical trials
10.g alternative hypotheses
10.h other



AD/PD™ Facebook
AD/PD™ Twitter
AD/PD™ Network

Keep Me Updated